Frontiers in Oncology · 2022 · 21 citations · 43 references
MedicineNeuroscienceOncologyBiomedical ImagingDiagnostic ImagingNeuro-oncologyBioluminescence ImagingBrain TumorsFluorescence ImagingGlioblastomaOptical Coherence TomographyTumor ImagingFluorescence DiagnosticsFluorescence LifetimeFluorescence Lifetime ImagingFluorescence Lifetime MeasurementsFluorescence Lifetime TomographyGlioblastoma ImagingGlioblastoma Tumor BiologyTumor Progression Monitoring
Development of the novel diagnostic and therapeutic approaches in neuro-oncology requires tumor models that closely reproduce the biological features of patients' tumors. Patient-derived xenografts (PDXs) are recognized as a valuable and the most "close-to-patient" tool for preclinical studies. However, their establishment is complicated by the factors related to both the surgical material and technique of the orthotopic implantation. The aim of this work was to develop a patient-derived glioblastoma multiform (GBM) model that stably co-expresses luciferase and a far-red fluorescent protein for monitoring of tumor progression in the brain and, using this model, to validate new diagnostic methods-macroscopic fluorescence lifetime imaging (macro-FLIM) and cross-polarization optical coherence tomography (CP OCT). The established model was similar to the original patient's GBM in terms of histological and immunohistochemical features and possessed reproducible growth in nude mice, which could be observed by both fluorescence and bioluminescence imaging. Our results demonstrated the high potential of macro-FLIM and CP OCT for intraoperative differentiation of GBM from the white matter. Thus, the dual-labeled PDX model of GBM proved to be an excellent approach for observation of tumor development by optical methods.
43
World Medical Association Declaration of Helsinki
JAMA · 2013 · 29.4K citations
Melissa C. Skala, Kristin M. Riching, Damian Bird et al. · Journal of Biomedical Optics · 2007 · 384 citations · Full text